Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03198767 · ClinicalTrials.gov registry record · Phase 2
Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT03198767 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 54 participants.
The verdict
NCT03198767, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as psyllium or calcium carbonate on alleviating diarrhea associated with LIK066.
Interventions
- DRUG LIK066
- DIETARY_SUPPLEMENT Carbohydrate 50%
- DIETARY_SUPPLEMENT Carbohydrate 25%
- DIETARY_SUPPLEMENT Carbohydrate 8%
- DIETARY_SUPPLEMENT Carbohydrate 0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2017-06-21 |
| Est. Completion | 2017-09-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03198767
The ClinicalTrials.gov registry entry for NCT03198767 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which LIK066 is the first listed.
NCT03198767 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03198767 about?
NCT03198767 is a clinical study titled "Effects of Carbohydrate in Diet and Supplements on the Gastrointestinal Tolerability of LIK066". The purpose of this study was to determine if LIK066 taken with a meal containing low carbohydrate is associated with less diarrhea compared to a high carbohydrate meal and to assess the potential effects of supplements such as psyllium or calcium carbonate on alleviating diarrhea associated with LI...
What is the current status of trial NCT03198767?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2017-06-21. Estimated completion is 2017-09-04.
What interventions are being tested in trial NCT03198767?
The interventions under investigation include: LIK066 (DRUG), Carbohydrate 50% (DIETARY_SUPPLEMENT), Carbohydrate 25% (DIETARY_SUPPLEMENT), Carbohydrate 8% (DIETARY_SUPPLEMENT), Carbohydrate 0% (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03198767?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.